Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.

Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D, Barlogie B, Tricot G.

Leuk Lymphoma. 1997 Oct;27(3-4):315-9.

PMID:
9402328
2.

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.

Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, Kumar SK, Dingli D, Dispenzieri A.

Ann Hematol. 2011 Jan;90(1):101-6. doi: 10.1007/s00277-010-1028-8. Epub 2010 Jul 20. Review.

PMID:
20645101
3.

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.

4.

The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.

Dinner S, Witteles W, Witteles R, Lam A, Arai S, Lafayette R, George TI, Schrier SL, Liedtke M.

Br J Haematol. 2013 May;161(3):367-72. doi: 10.1111/bjh.12269. Epub 2013 Feb 23.

PMID:
23432783
5.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.

PMID:
15566357
6.

Primary systemic amyloidosis.

Comenzo RL.

Curr Treat Options Oncol. 2000 Apr;1(1):83-9. Review.

PMID:
12057064
7.

Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.

Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, Rajkumar SV, Gertz MA, Kumar SK.

Mayo Clin Proc. 2010 Mar;85(3):232-8. doi: 10.4065/mcp.2009.0547.

8.

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA.

J Heart Lung Transplant. 2008 Aug;27(8):823-9. doi: 10.1016/j.healun.2008.05.016. Epub 2008 Jul 3.

PMID:
18656793
9.

Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma.

Giarin MM, Giaccone L, Sorasio R, Sfiligoi C, Amoroso B, Cavallo F, Cipriani A, Palumbo A, Boccadoro M.

Clin Chem. 2009 Aug;55(8):1510-6. doi: 10.1373/clinchem.2009.124370. Epub 2009 Jun 11.

10.

Al amyloidosis.

Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A; Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales.

Orphanet J Rare Dis. 2012 Aug 21;7:54. doi: 10.1186/1750-1172-7-54. Review.

11.

Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.

Jiang N, Qi C, Trieu Y, Reece D, Chang H.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1790-5. doi: 10.1016/j.bbmt.2011.05.009. Epub 2011 May 20.

12.

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.

Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.

Ann Hematol. 2010 Jun;89(6):579-84. doi: 10.1007/s00277-009-0874-8. Epub 2009 Dec 10.

PMID:
20012043
13.
14.

Amyloid arthropathy in the course of multiple myeloma.

Fautrel B, Fermand JP, Sibilia J, Nochy D, Rousselin B, Ravaud P.

J Rheumatol. 2002 Jul;29(7):1473-81.

PMID:
12136908
15.

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R.

Blood. 2003 May 15;101(10):3801-8. Epub 2002 Dec 19.

16.

Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies.

Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D.

Nephrol Dial Transplant. 1998 Jun;13(6):1438-45.

17.

Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.

Radovic V, Mijuskovic Z, Tukic Lj, Djurdjevic P, Stojanovic J, Zlatkovic M.

J BUON. 2012 Jan-Mar;17(1):110-5.

PMID:
22517703
18.
19.

Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.

Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Lacy M, Dispenzieri A, Rajkumar SV, Kyle RA, Leung N.

Am J Kidney Dis. 2012 Jun;59(6):786-94. doi: 10.1053/j.ajkd.2011.12.028. Epub 2012 Mar 13.

PMID:
22417785
20.

The occurrence of Al amyloidosis (light-chain amyloidosis) in patients with multiple myeloma in Lower Silesia Region, Poland.

Usnarska-Zubkiewicz L, Hołojda J, Jeleń M, Zubkiewicz-Zarębska A, Dębski J, Kuliczkowski K.

Adv Clin Exp Med. 2014 Mar-Apr;23(2):235-44.

Items per page

Supplemental Content

Write to the Help Desk